ARID1A, AT-rich interactive domain-containing protein 1A; BAP1, BRCA1-associated protein 1; BRAF, v-Raf murine sarcoma viral oncogene homolog B; BTC, biliary tract cancer; Biliary tract cancers; CCA, cholangiocarcinoma; CDKN2A/B, cyclin-dependent kinase inhibitor 2A/B; CK, cytokeratin; CLC, cholangiolocarcinoma; Cell of origin; Cholangiocarcinoma; CoH, Canal of Hering; DCR, disease control rate; ER, estrogen receptor; ERBB2/3, Erb-B2 Receptor Tyrosine Kinase 2/3; FGFR, fibroblast growth factor receptor; FGFR2, Fibroblast Growth Factor Receptor 2; GBC, gallbladder cancer; GEMM, genetically engineered mouse models; Genomics; HCC, hepatocellular carcinoma; HPCs, hepatic progenitor cells; IDH, isocitrate dehydrogenase; KRAS, Kirsten Rat Sarcoma Viral Oncogene Homolog; Lineage tracing; MET, Hepatocyte Growth Factor Receptor; MST1, Macrophage Stimulating 1; NA, not applicable; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; NGS, next-generation sequencing; NR, not reported; NTRK, Neurotrophic Receptor Tyrosine Kinase 1; ORR, objective response rate; OS, overall survival; PBG, peribiliary gland; PFS, progression- free survival; PIK3CA, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha; PLC, primary liver cancer; PRKACA/B, Protein Kinase CAMP-Activated Catalytic Subunit Alpha/Beta; PROM1, Prominin 1; PSC, primary sclerosing cholangitis; Personalized therapy; RNF43, Ring Finger Protein 43; SMAD4, SMAD Family Member 4; TBG, thyroid binding globulin; TP53, Tumor Protein P53; WHO, World Health Organization; dCCA, distal cholangiocarcinoma; eCCA, extrahepatic cholangiocarcinoma; iCCA, intrahepatic cholangiocarcinoma; mo, months; pCCA, perihilar cholangiocarcinoma